Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005 May 28;330(7502):1270; author reply 1270-1.
doi: 10.1136/bmj.330.7502.1270.

Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed

Lionel H Opie
Comment

Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed

Lionel H Opie. BMJ. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329: 1248-9. (27 November.) - PMC - PubMed
    1. Blood Pressure-Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362: 1527-35. - PubMed
    1. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288: 2981-97. - PubMed
    1. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low left ventricular ejection fraction trials. Circulation 2004;110: 2618-26. - PubMed
    1. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329: 828. - PMC - PubMed

MeSH terms

Substances